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Abstract
Background: Glaucoma is a complex neurodegeneration and a leading cause of blindness worldwide. Current
therapeutic strategies, which are all directed towards lowering the intraocular pressure (IOP), do not stop
progression of the disease. We have demonstrated that recombinant adeno-associated virus (rAAV) gene delivery of
a form of erythropoietin with attenuated erythropoietic activity (EpoR76E) can preserve retinal ganglion cells, their
axons, and vision without decreasing IOP. The goal of this study was to determine if modulation of
neuroinflammation or oxidative stress played a role in the neuroprotective activity of EPO.R76E.
Methods: Five-month-old DBA/2J mice were treated with either rAAV.EpoR76E or a control vector and collected at
8 months of age. Neuroprotection was assessed by quantification of axon transport and visual evoked potentials.
Microglia number and morphology and cytokine and chemokine levels were quantified. Message levels of oxidative
stress-related proteins were assessed.
Results: Axon transport and visual evoked potentials were preserved in rAAV.EpoR76E-treated mice. The number of
microglia was decreased in retinas from 8-month-old rAAV.EpoR76E-treated mice, but proliferation was unaffected.
The blood-retina barrier was also unaffected by treatment. Levels of some pro-inflammatory cytokines were
decreased in retinas from rAAV.EpoR76E-treated mice including IL-1, IL-12, IL-13, IL-17, CCL4, and CCL5. TNFα
messenger RNA (mRNA) was increased in retinas from 8-month-old mice compared to 3-month-old controls
regardless of treatment. Expression of several antioxidant proteins was increased in retinas of rAAV.EpoR76E-treated
8-month-old mice.
Conclusions: Treatment with rAAV.EpoR76E preserves vision in the DBA/2J model of glaucoma at least in part by
decreasing infiltration of peripheral immune cells, modulating microglial reactivity, and decreasing oxidative stress.
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Background
Glaucoma is the second leading cause of blindness
worldwide behind cataracts. The only modifiable risk
factor for glaucoma is intraocular pressure (IOP). How-
ever, there are patients with elevated IOP who do not
develop glaucoma and approximately one third of glau-
coma patients have normal-range IOP. All current med-
ical and surgical treatments focus on lowering IOP. This
approach can slow the progression of disease, even in
many normal-tension glaucoma patients, but often does
not stop it entirely at least in part due to poor patient
compliance in administering IOP lowering eye drops. As
a result of the above complexities, many laboratories are
focused on understanding the molecular events that
underlie axon degeneration in glaucoma with the hope
of intervening in the disease process in an IOP-
independent manner.
Glaucoma is an axonopathy meaning that the retinal
ganglion cell (RGC) axons in the optic nerve undergo
pathologic changes first, followed by death of the cell
bodies (for review see [1]). Several hypotheses have been
posited regarding the mechanisms that induce axon de-
generation in glaucoma including mechanical damage at
the optic nerve head [2–5], hypoxia and oxidative stress
(for reviews see [6–8]), and neuroinflammation (for re-
view see [9, 10]). Thus, an attractive neuroprotective
candidate would affect more than one of these processes.
One example is erythropoietin (EPO), a type I cytokine
that blocks apoptosis, preserves the blood-brain barrier,
counteracts oxidative stress, and limits glial reactivity
(for review see [11, 12]). Recent studies suggest that
EPO can modulate neuroinflammation independently of
its ability to block cell death (for review see [11]).
We previously demonstrated that recombinant adeno-
associated virus (rAAV)-mediated gene delivery of EPO
or EPO.R76E, a form of EPO with attenuated erythro-
poietic activity, prior to onset of elevated IOP preserved
the RGC axons, cell bodies, and vision in the well-
characterized DBA/2J mouse model of glaucoma [13].
Others have also shown that injections of EPO protein
are effective in glaucoma models [14, 15]. More recently,
we demonstrated that rAAV.EpoR76E is also effective in
an induced model of glaucoma suggesting that the pro-
tection was not specific to the particular mouse model
[16]. Further, therapeutic benefit was achieved in both
models when treatment was delayed until the onset of
elevated IOP although to a lesser extent than when rAA-
V.EpoR76E was provided earlier [16].
The goal of this study was to exploit the efficacy of
EPO in blocking glaucoma pathogenesis in order to in-
vestigate the mechanisms responsible for this axonopa-
thy in the DBA/2J model. We delivered rAAV.EpoR76E
into 5-month-old mice in order to yield maximal gene
expression when IOP starts to elevate in the DBA/2J
[17]. We assessed therapeutic efficacy at 6 and 8 months
of age, the age of onset of axon degeneration and prior
to RGC death in this model [18]. We investigated the
effect of EPO.R76E on neuroinflammation and oxidative
stress by quantifying numbers and morphology of mi-
croglial cells, levels of pro-inflammatory chemokines




DBA/2J mice were obtained from Jackson Laboratories
(Bar Harbor, ME). Mice were group-housed, maintained
on a 12-h light-dark cycle, and provided food and water
ad libitum. All experiments were approved by the Insti-
tutional Animal Care and Use Committee of Vanderbilt
University and were in accordance with the ARVO
Statement for the Use of Animals in Vision and Oph-
thalmic research, protocol number M/12/131. Animals
were injected in the quadriceps with 1 × 109 gc of
rAAV2/8.CMV.EpoR76E (rAAV.EpoR76E) or rAAV2/
8.CMV.eGFP (rAAV.eGFP). All viral vectors were pro-
duced by the University of Pennsylvania Vector Core
(Philadelphia, PA). Mice were injected at 5 months of
age and euthanized at 6 or 8 months of age.
Fluorescein angiography (FA)
Anesthetized mice were injected with 0.1 ml of fluores-
cein (AK-Fluor-10 %; Akom, Inc; Lake Forest, IL). Eyes
were dilated with 1 % tropicamide and 2.5 % phenyleph-
rine and lubricated with 2.5 % methylcellulose (Gonio-
visc Eye Care and Cure, Inc., Tuscon, AZ). Retinal
fluorescein was imaged on a Micron IV imaging system
(Phoenix Research Labs, Pleasanton, CA).
Flash visual evoked potential (fVEP)
The fVEPs were performed according to previously pub-
lished methods [13, 16]. Briefly, animals were dark-
adapted overnight and anesthetized with an intraperito-
neal injection of ketamine/xylazine/urethane (25/6/
600 mg/kg). Eyes were dilated with 1 % tropicamide and
then moistened with lubricating eye drops. The fur over
the visual cortex was removed, and platinum needle
electrodes (Grass Technologies, Warwick, RI) were
inserted subdermally over the left and right visual cortex.
Electrodes were placed at the snout and flank for the ref-
erence and ground, respectively. Animals were placed on
a warm platform under a Ganzfeld dome (Diagnosys
LLC, Lowell, MA). Two hundred flashes of white light at
an intensity of 1.0 cd · sec/m2 were presented to each
animal at a flash frequency of 1 Hz with a 500 ms inner
sweep delay. Data collection and analysis was performed
by a masked investigator.
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Anterograde transport analyses
Anterograde axon transport was assessed using previously
published methodology [19]. Briefly, anesthetized mice
(3 % isoflurane) received single, bilateral, intravitreal injec-
tions of 2 μL of 1 % cholera toxin subunit B (CTB) conju-
gated to AlexaFluor-594 (Life Technologies, Carlsbad,
CA) in phosphate-buffered saline (PBS) 48 h prior to col-
lection. Brains were post-fixed in 4 % paraformaldehyde
(PFA) for at least 48 h, the cortex was removed, and the
remaining tissue was cryoprotected in 30 % sucrose for
48 h. Fifty-micron-thick coronal sections through the su-
perior colliculus (SC) were obtained using a sliding micro-
tome. Sections were mounted in Fluoromount-G
(SouthernBiotech, Birmingham, AL), imaged on a Nikon
Eclipse Ti epifluorescence microscope (Melville, NY), and
CTB signal density in the SC was quantified using Image-
Pro Analyzer 7.0 software (Media Cybernetics Rockville,
MD) as previously described [19]. Briefly, each SC section
was divided into several bins from medial to lateral, and
average CTB signal density within each bin was calculated
by dividing the area of pixels above background by total
pixel area measured. A colorimetric scale ranging from
blue (0 % transport) to red (100 % transport) was used to
indicate average CTB signal density for each bin. Each sec-
tion was adjoined to the next in a rostral to caudal fashion
and then oriented to generate a retinotopic map of the
SC. Areas of transport deficit were subtracted from total
SC area to calculate percent intact transport. Fluorescence
quantification was performed by a masked investigator.
Immunohistochemistry
For immunohistochemistry, eyes were post-fixed in 4 %
PFA for at least 2 h and then whole retinas were iso-
lated. A subset were embedded in 5 % agarose, and 70-
μm-thick cross sections were collected on a vibratome.
Cross sections or retinal flat mounts were incubated
overnight at 4 °C in 5 % normal donkey serum in 0.1 %
Triton X-100, 0.5 % BSA, 0.1 % Azide, and PBS (PBTA).
Sections or flat-mounted retinas were then incubated
overnight at 4 °C in primary antibody in PBTA, rinsed
with PBTA, and then incubated overnight at 4 °C in sec-
ondary antibody in PBTA. Primary antibodies used: goat
anti-Iba-1 (1:100; Abcam, Cambridge, UK), rabbit anti-
Ki-67 (1:100; Thermo Fisher Scientific, Waltham, MA),
and chicken anti-H-ferritin (1:50; Abcam, Cambridge,
UK). Appropriate secondary antibodies conjugated to
AlexaFluors were obtained from Life Technologies
(1:200; Carlsbad, CA). Whole retinas were flat-mounted
RGC side up. Both whole retinas and sections were
mounted in Fluoromount-G (SouthernBiotech, Birming-
ham, AL), and 20-μm-thick z-stack images were col-
lected on an Olympus FV-1000 confocal microscope
(Center Valley, PA) using a ×60 oil immersion lens. Im-
aging on the confocal microscope was performed
through the use of the Vanderbilt University Medical
Center Cell Imaging Shared Resource.
The number of IBA1+ and IBA1 and Ki67+ cells were
quantified in 27 high-power views of four retinas per
treatment condition. A total of 207 and 168 IBA-1 posi-
tive cells were assessed from retinas of mice injected
with rAAV.eGFP or rAAV.EpoR76E, respectively. Im-
munofluorescence of H-ferritin was quantified according
to previously published methods [20]. Briefly, ×60 mag-
nification confocal micrographs at a 10-μm depth within
the tissue were used for quantification. Fluorescence in-
tensity from the ganglion cell layer to the outer plexi-
form layer was quantified and averaged using ImageJ
software. The intensity was normalized based on total
area of retina assessed.
Microglial quantification and morphometrics
Flat-mounted retinas immunolabeled with Iba-1 were
imaged through the inner plexiform layer (IPL) begin-
ning just below the RGC layer in five central and five
peripheral areas. All microglial analyses were conducted
by a masked investigator using ImagePro Analyzer 7.0
software. In each z-stack image, microglia number and
soma area were quantified. Ramification number for
each microglial cell was determined by counting inter-
sections of glial processes with a 10 × 10 μm grid
overlay.
Multiplex ELISA
Retinas were sonicated and run in singlet on the Milli-
plex MAP Mouse Cytokine/Chemokine Magnetic Bead
Panel I 25-plex assay per manufacturer’s protocol (EMD
Millipore, Billerica, MA). Plates were read on a Luminex
MAGPIX with xPONENT software (Thermo Fisher Sci-
entific, Waltham, MA) using settings stated in the man-
ufacturer’s protocol. Multiplex ELISA plates were read
and analyzed through the use of the Vanderbilt Hor-
mone Assay and Analytical Services Core.
Quantitative reverse transcription-PCR
Retinas were homogenized, and RNA was extracted using
a Qiagen RNeasy kit (Valencia, CA). RNA concentration
and purity was measured on a spectrophotometer. A first-
strand complementary DNA (cDNA) library was synthe-
sized from 250 ng of RNA from each sample using the
Superscript III First-Strand synthesis system (Invitrogen,
Waltham, MA) and oligo-dT20 primers. Quantitative PCR
(qPCR) was performed using Power SYBR green master
mix (Applied Biosystems, Waltham, MA). All primer se-
quences were obtained from previous studies; we assessed
the following: iNOS, arginase 1, IL-1β, IL-6, TNFα, TGFβ,
IL-4, and IL-10 [21–24]. All qPCR was performed in du-
plicate using the Applied Biosciences 7300 real-time PCR
system (Waltham, MA). The assay was performed in
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duplicate on 13 retinas per condition. The amplification
threshold was set using system software. Relative changes
in gene expression were determined using glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) as an internal con-
trol [25]. There was no significant change between sam-
ples in GAPDH levels.
Oxidative stress PCR array
The same cDNA as was used for the quantitative PCR
analysis was also used in an RT2 Profiler mouse oxida-
tive stress PCR array kit per manufacturer’s instructions
(Qiagen, Valencia, CA). The cDNA from each group was
pooled to have sufficient material for the assay.
Statistical analysis
All statistical analyses were performed using GraphPad
Prism software (La Jolla, CA). A two-way ANOVA with
a Bonferroni post hoc test was performed for the
hematocrit time course. A one-way ANOVA with a Bon-
ferroni post hoc test (α = 0.05) was used to analyze an-
terograde transport data, microglia morphometric data,
ON quantification data, and fVEP latencies. Percent
baseline fVEP amplitudes and results from the multiplex
ELISA were compared using an unpaired Student’s t test
(α = 0.05). A one-way ANOVA and Dunnett’s multiple
comparisons post hoc test (α = 0.05) were used to
analyze the qPCR results. Means and standard deviation
were calculated for each data set.
Results
Delayed treatment with rAAV.EpoR76E protects against
vision loss in the DBA/2J model of glaucoma
Maximal protein production from rAAV2/8-mediated
transgene delivery after an intramuscular injection is
typically achieved 3 weeks after injection [17]. Since
EPO.R76E causes a mild elevation in hematocrit, we
used that as a physiological read-out of EPO.R76E pro-
duction. There was no statistically significant difference
in hematocrit levels in rAAV.EpoR76E-injected mice as
compared to averaged baseline/rAAV.eGFP-injected
mice (see line, Fig. 1a) until 4 weeks after gene delivery
(p < 0.01; Fig. 1a). This elevation was retained for the
duration of the study (12 weeks). While the increase in
hematocrit at 3 weeks was not statistically significant,
the average was the same as that detected at 12 weeks
(47 %, as compared to 44 % in the rAAV.eGFP group).
The only difference is that we only have an “n” of 3 at
3 weeks but an “n” of 23 at 12 weeks. Since the elevation
in hematocrit is so slight, it was not sufficient to result
in a statistical significance at 3 weeks. For this reason,
and the fact that hematocrit is a physiological read-out
rather than a direct measure of EPO.R76E levels, our
data is still consistent with an onset of significant trans-
gene expression at 3 weeks after injection. Since mice
were injected at 5 months of age, the increase in
EPO.R76E correlates to 5.75 months of age (arrow,
Fig. 1b). The average increase in hematocrit was com-
parable to our previous results with rAAV.EpoR76E
(Fig. 1a) [13, 26, 27]. We have previously demonstrated
that EPO.R76E enters the eye after systemic rAAV gene
delivery [16, 28]. The elevation in IOP was variable, con-
sistent with this model, but reached statistical signifi-
cance compared to 3 months in both groups by
5.5 months of age (Fig. 1b). Consistent with our previous
studies, there was no difference in IOP elevation be-
tween mice that received rAAV.eGFP and those that re-
ceived rAAV.EpoR76E (Fig. 1b) [13, 16].
Active anterograde axon transport from the RGC to
the SC was quantified according to previously published
methods to assess axon integrity [16, 19]. The heat map
of fluorescence intensity shows intact axon transport in
the 3-month-old DBA/2J mice (Fig. 1c). There was de-
creased axon transport particularly along the caudal
edge of the SC from 8-month-old DBA/2J mice treated
with rAAV.eGFP (Fig. 1d). In contrast, axon transport
appeared completely preserved in the 8-month-old
DBA/2J mice that received rAAV.EpoR76E (Fig. 1e). The
fluorescence in the SC was quantified to determine the
percent intact transport (Fig. 1f ). The 3-month-old mice
exhibited 99 ± 0.9 % (avg ± s.d., n = 4) intact transport.
Consistent with the original characterization of the
DBA/2J, axon transport deficits were just beginning to
occur at 8 months of age 92 ± 7.6 % (n = 11) with two
populations of mice clearly evident and statistically sig-
nificant by Bartlett’s test of variance, p < 0.0001. At this
early time-point, only 27 % of the axons exhibited axon
transport levels similar to the 3-month control, while
45 % had axon transport levels below 95 % (lowest was
78 %). In contrast, 83 % of the axons from mice treated
with rAAV.EpoR76E had a percent axon transport of
greater than 95 % (n = 11).
Consistent with our results in 10-month-old DBA/2J
mice [13, 16], there was no effect of glaucoma or rAA-
V.EpoR76E on the fVEP N1 or P1 latency at 6 or
8 months of age (data not shown). There was a statisti-
cally significant decrease in both the N1 (Fig. 1g) and P1
(Fig. 1h) amplitudes at 6 (p < 0.01) and 8 months (p <
0.001) of age in mice injected with rAAV.eGFP as com-
pared to 3-month-old DBA/2J controls. The N1 and P1
amplitudes in mice treated with rAAV.EpoR76E were
not different from 3-month-old DBA/2J mice or rAA-
V.eGFP-injected mice suggesting a moderate protective
effect by rAAV.EpoR76E.
Microglia number, but not proliferation, was significantly
decreased by rAAV.EpoR76E
In order to assess a role for neuroinflammation, we ex-
amined relevant molecular and cellular changes at
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8 months, a time-point prior to cell death and at the be-
ginning stages of axon degeneration in the DBA/2J [18].
Increases in microglial number and reactivity are de-
tected as early as 3 months of age, prior to the onset of
elevated IOP in this model [29]. The alteration in micro-
glia occurs first in the central retina and expands to the
peripheral retina over time [29]; thus, we report changes
in the central and peripheral retina separately.
Microglia in the inner plexiform layer of the retina ap-
peared increased in the 8-month-old DBA/2J mice
injected with rAAV.eGFP as compared to those treated
with rAAV.EpoR76E (Fig. 2a, b). Quantification yielded
an average number of IBA-1-positive microglia in the
central retinas of 3-month-old mice and 8-month-old
rAAV.eGFP- and rAAV.EpoR76E-treated mice of 9.3 ±
3.4, n = 15; 14 ± 4.2, n = 25 (p < 0.01 vs 3 month); and 10
± 4.1, n = 30 (n.s. vs 3 month), respectively (Fig. 2e). The
difference in the number of microglia in the central ret-
inas of rAAV.eGFP- and rAAV.EpoR76E-treated mice
was also statistically significant, p < 0.05. The average
number of microglia in regions of the peripheral retina
of 3-month-old mice and 8-month-old rAAV.eGFP- and
A B
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Fig. 1 Treatment with rAAV.EpoR76E at 5 months protects against vision loss at 6 and 8 months of age. a Graph of hematocrit level over time in mice
after systemic injection of rAAV.EpoR76E compared to baseline levels in rAAV.eGFP-injected mice (line) showing a statistically significant increase at 4 and
12 weeks. b Graph of IOP level over time showing a statistically significant increase by 5.5 months of age in both rAAV.eGFP- and rAAV.EpoR76E-treated
mice as compared to levels at 3 months of age. There was no difference between treatment groups at any time-point. Arrow indicates when an increase
in hematocrit was first detected after gene delivery of EpoR76E. c–e Representative SC fluorescence heat maps of (c) 3-month-old mice, (d) 8-month-old
mice treated with rAAV.eGFP, and (e) 8-month-old mice treated with rAAV.EpoR76E. Orientation labels in (c) apply to all heat maps. f Scatter plot of
percent axon transport to the SC. The red circle indicates optic nerves with poor axon transport, note the lack of nerves with poor transport in the
rAAV.EpoR76E-treated cohort, p< 0.0001 by Bartlett’s test. g Box and whisker plots of fVEP N1 peak amplitude shown as absolute values. h Box and whisker
plots of fVEP P1 peak amplitude. The amplitudes in the rAAV.eGFP-treated mice were decreased as compared to 3-month-old controls. There was no
statistically significant difference between the rAAV.EpoR76E-treated mice and either other group. *p< 0.05, **p< 0.01, ***p< 0.001, and #p< 0.0001
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rAAV.EpoR76E-treated mice was 8.7 ± 2.7, n = 15; 16 ±
5.5, n = 24 (p < 0.001 vs 3 month); and 12 ± 3.8, n = 30
(n.s. vs 3 month), respectively (Fig. 2f ). The difference in
the number of microglia in the peripheral retinas of
mice treated with rAAV.eGFP or rAAV.EpoR76E-treated
mice was also statistically significant, p < 0.01.
To determine if the decrease in microglia was due to in-
hibition of microglial proliferation, we performed double
immunolabeling with the microglial marker, anti-IBA1,
and anti-Ki67, a marker for proliferating cells. Double-
labeled cells were evident in 8-month-old retinas treated
with either rAAV.eGFP (Fig. 2c) or rAAV.EpoR76E
(Fig. 2d). An average of 51 ± 4.2 % (SEM) of IBA-1-
positive microglia were Ki67-positive in retinas from rAA-
V.eGFP-injected 8-month-old mice (Fig. 2g). Similarly, in
retinas from rAAV.EpoR76E-treated mice, 44 ± 6.9 % of
IBA-1-positive microglia were Ki67-positive.
The retinal vasculature was assessed by fluorescein
angiography to determine if the decrease in number of
microglial cells was due to preservation of the blood-
retina barrier by EPO.R76E. In the normal, non-
glaucomatous, retina, fluorescein is retained within the
blood vessels (Fig. 2h). However, in the glaucomatous
DBA/2J, retina leakage of fluorescein was detected re-
gardless of treatment (Fig. 2i, j).
EPO.R76E-modulated microglial morphology in 8-month-
old DBA/2J mice
To determine if rAAV.EpoR76E altered the reactive state
of the microglia, the morphology of the cells was
assessed both in the central and peripheral retina. In 3-
month-old control retinas, most microglial cells had
small somas and highly stratified, thin processes (Fig. 3a).







Fig. 2 Treatment with rAAV.EpoR76E reduced the number, but not proliferation, of microglia in the retina. a, b Representative confocal
micrographs of IBA-1 immunolabeling (green) of flat-mounted retinas from 8-month-old mice treated with rAAV.eGFP (a) or rAAV.EpoR76E (b). c,
d Representative confocal micrographs of anti-IBA-1 (blue) and anti-Ki67 (green) double-labeling in retinal sections from 8-month-old mice treated
with rAAV.eGFP (c) or rAAV.EpoR76E (d). e, f Box and whisker plots showing quantification of microglia number in the central (e) and peripheral (f)
retinas. *p < 0.05, **p < 0.01, and ***p < 0.001. g Box and whisker plots of the percentage of anti-IBA-1-positive cells that were also anti-Ki67-
positive. There was no statistically significant difference between rAAV.eGFP- and rAAV.EpoR76E-treated mice. h–j Representative fluorescein angiography
in a normal retina (h) and glaucomatous retinas from mice treated with rAAV.eGFP (i) or rAAV.EpoR76E (j)
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Fig. 3 Treatment with rAAV.EpoR76E altered microglial morphology. a–f Representative high-magnification confocal micrographs of IBA-1
immunolabeled (green) microglia in 3-month-old (a) and 8-month-old (b–f) retinas. These morphologies were present in retinas from both
treatment groups. g, h Box and whisker plots of microglial soma area of cells from the central (g) or peripheral (h) retina, ****p < 0.0001. i, j Box
and whisker plots of microglial ramification number for cells from the central (i) or peripheral (j) retina, *p < 0.05. k, l Scatter graphs of microglial
soma area versus soma number in the central (k) or peripheral (l) retina. m, n Scatter graphs of microglial soma area versus ramification number
in the central (m) or peripheral (n) retina
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microglial morphologies were detected in glaucomatous
retinas including larger cell bodies and shortened pro-
cesses (Fig. 3b–f ). The ranges of microglial morphologies
are shown, starting with thicker processes and ending with
amoeboid morphologies. Examples of all stages were de-
tected in retinas from both rAAV.eGFP- and rAAV.E-
poR76E-injected 8-month-old DBA/2J mice.
The average soma area in the central and peripheral
regions of retinas from 3-month-old mice was 328 ±
93 μm2 (n = 139 cells) and 320 ± 108 μm2 (n = 131 cells),
respectively (Fig. 3g, h). These values were statistically
different from the soma size in retinas from 8-month-
old mice regardless of treatment, p < 0.0001. In addition,
there was a statistically significant difference in soma
area in the central retinas of the rAAV.eGFP (698 ±
296 μm2, n = 357 cells)- and rAAV.EpoR76E (598 ±
221 μm2, n = 289 cells)-treated 8-month-old mice, p <
0.0001 (Fig. 3g). In contrast, the difference between the
treatment groups in the peripheral retina at 8 months
was not statistically significant. We detected 578 ±
204 μm2 (n = 394 cells) and 535 ± 184 μm2 (n = 312) in
retinas from rAAV.eGFP- and rAAV.EpoR76E-treated
mice, respectively (Fig. 3h). As expected, the soma area
was larger in both 8-month groups in the central retina
as compared to peripheral retina, matching a previous
study [29].
The average number of microglial ramifications in
the 3-month central and peripheral retina was 61 ± 32
(n = 121 cells) and 63 ± 43 (n = 103 cells), respectively
(Fig. 3i, j). The microglia in the central retinas of the
8-month-old DBA/2J mice had a similar number of
ramifications regardless of treatment, 62 ± 47 (n = 329
cells) and 64 ± 50 (n = 285 cells) in the rAAV.eGFP-
and rAAV.EpoR76E-treated mice, respectively (Fig. 3i). In
contrast, more ramifications were detected in the 8-
month-old peripheral retina compared to the central ret-
ina regardless of treatment (p < 0.001). A similar number
of microglial ramifications were detected in cells from the
peripheral retina; there was an average of 88 ± 48 (n = 367
cells) ramifications in the rAAV.eGFP-treated mice and
87 ± 59 (n = 310 cells) in the rAAV.EpoR76E-treated mice
(Fig. 3j).
By plotting the soma area against soma number, the
moderate effect of rAAV.EpoR76E on microglia morph-
ology becomes more apparent (Fig. 3k, l). The microglia
from 3-month-old retinas are primarily clumped to-
gether with a soma area under 500 μm2 and a ramifica-
tion number of under 100. In contrast, there was
significant variability in the morphology of the microglia
from retinas of 8-month-old rAAV.eGFP-treated mice.
The microglial response in the 8-month-old retinas of
rAAV.EpoR76E-treated mice was more restricted than
the rAAV.eGFP-treated mice, but the soma size and
ramification numbers were still elevated as compared to
the 3-month controls. Similarly, by plotting soma area
against ramification number, it is again apparent that
treatment with rAAV.EpoR76E dampens the reactivity of
the microglia but does not restore them entirely to a
quiescent state (Fig. 3m, n).
Retinas from rAAV.EpoR76E-treated mice had lower levels
of pro-inflammatory cytokines/chemokines
Another measure of neuroinflammation is the level of
cytokines and chemokines that are produced by reactive
glia (microglia, astrocytes, and Müller cells). We de-
tected statistically significant (p < 0.05) decreases in
some pro-inflammatory cytokines (Fig. 4a). As compared
to rAAV.eGFP, we detected 18, 16, 15, 28, 29, 85, 31,
and 24 decreases in IL-1α, IL-1β, IL-17, IL-12p40, IL-
12p70, CCL4 (MIP-1β), CCL5 (RANTES), and IL-13,
respectively, in retinas from mice treated with rAAV.E-
poR76E. There were no statistically significant differences
between the rAAV.eGFP and rAAV.EpoR76E retina levels
of other pro-inflammatory cytokines/chemokines: TNFα,
IL-6, CCL2, CXCL10, IL-2, IL-7, MIP 2, IFNγ, GM-CSF,
IL-10, IL-5, G-CSF, IL-9, CXCL1, CCL3 (MIP1α), and IL-
4 (data not shown).
We also measured messenger RNA (mRNA) levels for
markers of reactive microglia. There was no change de-
tected in levels of IL-1β, iNOS, arginase-1, IL-4, IL-6,
IL-10, or TGFβ message compared to 3-month controls
or between treatment groups. In contrast, there was a
statistically significant increase in mRNA for TNFα in
the rAAV.eGFP group (p < 0.05) and rAAV.EpoR76E (p
< 0.01) retinas as compared to the 3-month controls
(Fig. 4b). This calculated to a fold increase in TNFα
mRNA of 6.3 ± 1.9 (avg ± SEM) and 9.4 ± 3.1 in rAA-
V.eGFP- and rAAV.EpoR76E-treated mice, respectively,
as compared to 3-month controls (Fig. 4c).
Retinas from rAAV.EpoR76E-treated mice had increased
levels of antioxidant enzymes
Glaucoma pathogenesis is associated with neuroinflam-
mation, hypoxia, and mitochondrial dysfunction, all of
which result in oxidative stress [8–10, 30]. EPO.R76E, al-
though to a lesser extent than wild-type EPO, does in-
crease erythropoiesis and therefore may increase
oxygenation to the retina. To test this hypothesis, we
performed immunolabeling for H-ferritin, a sensitive
measure of tissue iron levels (Fig. 5a–c) [31]. Tissue H-
ferritin is increased when hepcidin levels are reduced as
a result of increased erythropoiesis [32, 33]. The labeling
pattern was unchanged between groups; however, quan-
tification of inner retina fluorescence showed an increase
in the retinas from rAAV.EpoR76E-treated mice as com-
pared to those injected with rAAV.eGFP (Fig. 5d).
Further, EPO can activate NF-E2-related factor 2
(Nrf2) to induce gene expression from the antioxidant
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C
Fig. 4 Treatment with rAAV.EpoR76E causes a decrease in pro-inflammatory cytokines and chemokines. a Bar graph of the percent decrease in
pro-inflammatory cytokines in retinas from 8-month-old rAAV.EpoR76E-treated mice as compared to mice treated with rAAV.eGFP, *p < 0.05. b, c
TNFα mRNA levels are increased in glaucoma and unaffected by treatment with rAAV.EpoR76E. Box and whisker plots of the delta Ct (b) and fold
change (c) in TNFα mRNA in 3-month-old and 8-month-old mice treated with rAAV.EpoR76E or rAAV.eGFP, *p < 0.05
E F
A B C D
Fig. 5 Treatment with rAAV.EpoR76E increases expression of several antioxidant proteins and increases H-ferritin in the retina. a–c Representative
confocal micrographs of H-ferritin immunolabeling in retinas from 3-month controls (a), 8-month-old mice injected with rAAV.eGFP (b), and
8-month-old mice treated with rAAV.EpoR76E (c). d Bar graph quantification of H-ferritin immunofluorescence showing a statistically significant
increase in the rAAV.EpoR76E-treated group as compared to rAAV.eGFP-injected mice. e Bar graph of mRNAs with increased expression in
8-month glaucomatous retina as compared to 3-month controls regardless of treatment. f Bar graph of mRNAs with increased expression in
retinas from rAAV.EpoR76E-treated 8-month-old mice as compared to age-matched rAAV.eGFP-injected mice
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response element (ARE) [34]. Therefore, we investigated
if EPO.R76E altered expression levels of oxidative stress-
related proteins in the glaucomatous DBA/2J mouse ret-
ina at 8 months (Fig. 5e, f ). A twofold or greater increase
was detected in BCL2/adenovirus E1B 19 kDa interact-
ing protein 3 (Bnip3), eosinophil peroxidase (Epx), and
glutathione peroxidase 5 (Gpx5) as compared to 3-
month-old controls regardless of treatment (Fig. 5e). Ex-
pression of Bnip3 is induced by hypoxia inducible factor
1α (HIF-1 α); the protein is localized to the mitochon-
drial outer membrane where it can both induce mito-
phagy of mitochondria and activate apoptosis (for review
see [35]). Increases in Gpx5 have been reported in glau-
coma patients [36, 37]. Levels of antioxidant 1 copper
chaperone (Atox1), cytoglobin (Cygb), and sirtuin 2
(Sirt2) were elevated 1.5-fold in both groups as com-
pared to 3-month controls (Fig. 5e). ATOX1 is an anti-
oxidant against superoxide and hydrogen peroxide.
CYGB is expressed in retinal neurons where it can bind
oxygen to prevent oxidative stress. Altogether, the in-
crease in expression of these enzymes suggests that the
retina enacts an endogenous protective response against
oxidative stress early in glaucoma.
There was an increase of 1.5-fold or greater in aldehyde
oxidase 1 (Aox1) also known as retinal oxidase [38, 39],
NADPH quinone oxidoreductase 1 (Nqo1), the mitochon-
drial inner membrane protein (Mpv17), Gpx7, nucleoside
diphosphate-linked moiety X-type motif 1 (Nudt1), Gpx4,
and selenoprotein P plasma 1 (Sepp1) in the retinas from
rAAV.EpoR76E as compared to rAAV.eGFP-treated 8-
month-old glaucomatous mice (Fig. 5f ). The increase
in Aox1 was a surprise as it produces hydrogen per-
oxide and can also catalyze the formation of super-
oxide. The remaining mRNAs encode antioxidant
enzymes, several of which are associated with the
mitochondria (Nqo1, Nudt1, and Gpx). Sepp1 is inter-
esting in that it encodes an extracellular glycoprotein
that has an antioxidant role and appears to be associ-
ated with endothelial cells [40].
Discussion
We detected a deficit in vision at 6 months of age, prior
to a quantitative decrease in axon transport or axon de-
generation, suggesting that the fVEP may be the earliest
indicator of disease progression in this well-recognized
progressive model of pigment dispersion glaucoma. The
time course assessed in this study also revealed that de-
livery of rAAV.EpoR76E at the earliest sign of elevated
IOP (5 months) preserved axon transport as soon as
1 month later. The serotype of rAAV that we used in
this study results in gene expression approximately
3 weeks after injection [17], so it is impressive that pres-
ervation of vision was already detectable at 6-months,
after only 1 week of peak gene expression. This
treatment effect is also long-lasting [13, 16], making it
ideal for glaucoma, a slow, progressive disease. Finally,
treatment with EPO.R76E is safer than wild-type EPO
because it does not cause a dangerous rise in hematocrit
[13, 26, 27, 41].
The blood-retina barrier is disrupted both in patients
and in the DBA/2J model [42–44], and the DBA/2J
mouse demonstrates enhanced transendothelial mono-
cyte migration into the optic nerve head that contributes
to disease pathogenesis [44]. Further, others have shown
that EPO preserves the blood-brain barrier in models of
brain injury by blocking endothelial cell death and astro-
cyte hypertrophy (for review see [11]), and we have pre-
viously shown that EPO.R76E retains these activities in
in vitro assays [28, 45]. Despite this, the blood-retina
barrier appeared equally disrupted in both rAAV.eGFP-
and rAAV.EpoR76E-treated groups in this study. Thus,
the decrease in number of microglial cells by rAAV.E-
poR76E was neither due to inhibition of proliferation
nor from preservation of the blood-retina barrier. Ra-
ther, our results show that treatment with rAAV.E-
poR76E resulted in lower levels of several molecules
known to promote the recruitment and infiltration of
Th1 cells from the periphery: IL-12p40 (part of IL-23)
[46], CCL4, and CCL5 (for review see [47]), with the de-
crease in CCL4 being particularly dramatic.
In addition to decreasing the number of microglial
cells, treatment with rAAV.EpoR76E modulated the
microglial response to glaucoma in the DBA/2J. EPO is
anti-apoptotic and thus could limit neuroinflammation
by blocking cell death (for review see [12]). However,
this is unlikely to explain our results since the analyses
were performed at a time-point prior to the onset of sig-
nificant RGC death [18]. The decrease in levels of pro-
inflammatory cytokines/chemokines in retinas from
rAAV.EpoR76E-treated mice could be due to the pres-
ence of fewer microglia. Alternatively, it could reflect de-
creased production from macroglial cells (astrocytes and
Müller cells) or the remaining microglial cells. The mor-
phometric analysis shows that treatment with rAAV.E-
poR76E did not completely block microglial reactivity.
We posit that this is an advantage of EPO therapy since
in other models, blocking the microglial response en-
tirely can worsen neurodegeneration while modulating it
is neuroprotective (for review see [48]).
The lack of difference in TNFα levels between the two
treatment groups was unexpected considering EPO has
been reported to decrease levels of TNFα in the lipo-
polysaccharide model of ocular inflammation [49, 50]. It
is possible that glaucoma might induce TNFα produc-
tion through a different signaling pathway than that acti-
vated by lipopolysaccharide [49, 50]. The lack of
correlation between microglia number and TNFα levels
suggests that the majority of TNFα in the glaucomatous
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retina may be produced by reactive macroglia rather
than microglia. This is supported by a previous study
that demonstrated production of TNFα from primary
retinal astrocytes and Müller cells under stress condi-
tions [51]. This, in turn, may suggest that systemic gene
delivery of EPO.R76E had little to no effect on the re-
activity of these macroglial cells. We have previously
demonstrated decreased glial reactivity after intraocular,
but not systemic, delivery of EPO suggesting a possible
dose-dependent effect (our unpublished data) [45]. In
addition, the detection of neuroprotection by EPO.R76E
despite a lack of decrease in TNFα levels suggests that
EPO.R76E acts downstream or independent of the TNFα
pathway.
TNFα can activate the caspase cell death cascade, in-
duce mitochondrial dysfunction, and cause oxidative
damage [51, 52]. Since the current study was performed
prior to initiation of cell death in this model, that mech-
anism is less relevant [18]. EPO can decrease oxidative
stress, at least in part, through activation of Nrf-2 and
the ARE (for review see [11]) [34]. We detected in-
creased expression of several antioxidant enzymes and
proteins in the retinas of rAAV.EpoR76E-treated mice
including those involved in mitochondrial function
(Nqo1, Nudt1, Gpx). Therefore, independent of modula-
tion of neuroinflammation, EPO.R76E may protect
against glaucomatous neurodegeneration by directly
counteracting oxidative stress. If this is the major path-
way for neuroprotection by EPO.R76E, then increasing
expression of Nrf2 may be just as effective. In support of
this approach, others have shown that chemically in-
duced activation of Nrf2 protects RGCs in the optic
nerve crush model of RGC death [53].
Finally, hypoxia has been implicated as a major
contributor to glaucoma pathogenesis [8]. The hy-
pothesis states that damage to the microvasculature at
the optic nerve head leads to hypoxic events. This hy-
pothesis is supported by studies showing an increase
in levels of HIF1α in the vitreous of glaucoma pa-
tients and in animal models [54, 55]. A major target
of HIF1α is EPO and both hypoxic pre-conditioning
and systemic treatment with EPO are protective to
retinal neurons [56, 57]. EPO expression is also in-
creased in glaucoma patients and in a rat model of
ocular hypertension suggesting that it may represent
an endogenous protective mechanism [58–62]. Sys-
temic exogenous EPO can increase tissue oxygen de-
livery as a result of increased erythropoiesis. We
detected an increase in H-ferritin immunofluorescence
in the retinas of rAAV.EpoR76E-treated mice suggest-
ing that although erythropoiesis was significantly at-
tenuated as compared to that induced by wild-type
EPO, it was still sufficient to increase blood flow to
the retina.
Conclusions
The current results support findings from other groups
that neuroinflammation, hypoxia, and oxidative stress
play a role in glaucoma pathogenesis (for review see [8–
10, 30]). We expect that the most successful neuropro-
tective approach for a complex neurodegenerative dis-
ease such as glaucoma will require blocking neuronal
cell death as well as normalizing the environment, in-
cluding restoring appropriate glial support. We have
shown that EPO.R76E is a very promising therapeutic to
accomplish this goal.
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